A comparative investigation of CC chemokines and SIV suppressor factors generated by CD8+ and CD4+ T cells and CD14+ monocytes.
The capacity of CD8+ and CD4+ T cells and CD14+ monocytes to generate the CC chemokines, RANTES, MIP-1alpha and MIP-1beta, and SIV suppressor factors were studied using cells separated from PBMC of macaques immunized with the 70-kDa heat shock protein (HSP70). Unimmunized macaques showed low levels of the three CC chemokines and SIV-SF, and they showed little variation between PBMC and the two subsets of T cells stimulated with PHA. Immunization with HSP70 elicited an increase in the in vitro concentration of each of the three CC chemokines and SF. This was found with PBMC, CD4+ and CD8+ T cells and to a lesser extent with monocytes, when conventionally separated enriched cell subsets were examined from the same PBMC. However, the concentrations of the three CC chemokines derived from highly purified cell-sorted populations (>95%) were greatly increased, as compared with the enriched cell subsets. The concentration of each of the three chemokines was highest for CD8+ T cells, decreased with CD4+ T cells and was lowest with the CD14+ monocytes, but the latter were not stimulated. Neutralization assays with antibodies to the three CC chemokines showed that the antiviral activity generated by the four populations of cells could be largely accounted for by the three CC chemokines. The results of this comparative study suggests that CD8+ as well as CD4+ T cells and CD14+ monocytes generate the three CC chemokines and SIV-SF when stimulated with a mitogen, and that the baseline innate level can be upregulated by adaptive immune responses to a specific antigen.
Peter Gorer Department of Immunobiology, Guy's, King's and St. Thomas' Hospital Medical Schools, London, UK.
Kaboutar
K
Babaahmady
Lesley A
LA
Bergmeier
Trevor
T
Whittall
Mahavir
M
Singh
Yufei
Y
Wang
Thomas
T
Lehner
D000818:Animals; D000998:Antiviral Agents / Q000037:antagonists & inhibitors / Q000096:biosynthesis* / Q000378:metabolism; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology / Q000378:metabolism* / Q000821:virology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology / Q000378:metabolism* / Q000821:virology; D002469:Cell Separation / Q000379:methods; D054405:Chemokine CCL3; D054407:Chemokine CCL4; D018946:Chemokine CCL5 / Q000096:biosynthesis / Q000276:immunology / Q000378:metabolism; D019742:Chemokines, CC / Q000096:biosynthesis* / Q000276:immunology / Q000378:metabolism; D018840:HSP70 Heat-Shock Proteins / Q000008:administration & dosage / Q000276:immunology / Q000494:pharmacology; D007114:Immunization; D007074:Immunoglobulin G / Q000494:pharmacology; D007273:Injections, Intramuscular; D007963:Leukocytes, Mononuclear / Q000276:immunology; D018950:Lipopolysaccharide Receptors / Q000096:biosynthesis*; D008213:Lymphocyte Activation; D008253:Macaca mulatta; D019402:Macrophage Inflammatory Proteins / Q000096:biosynthesis / Q000276:immunology / Q000378:metabolism; D009000:Monocytes / Q000276:immunology / Q000378:metabolism* / Q000821:virology; D009500:Neutralization Tests; D010835:Phytohemagglutinins / Q000494:pharmacology; D015302:Simian Immunodeficiency Virus / Q000276:immunology*; D013491:Suppressor Factors, Immunologic / Q000096:biosynthesis* / Q000378:metabolism
D000998:Antiviral Agents; D054405:Chemokine CCL3; D054407:Chemokine CCL4; D018946:Chemokine CCL5; D019742:Chemokines, CC; D018840:HSP70 Heat-Shock Proteins; D007074:Immunoglobulin G; D018950:Lipopolysaccharide Receptors; D019402:Macrophage Inflammatory Proteins; D010835:Phytohemagglutinins; D013491:Suppressor Factors, Immunologic